Ex-Palantir engineers raise $12M for AI drug platform

Perceptic, a startup founded by three former Palantir executives, has emerged from stealth with a $12 million seed funding round to build an end-to-end AI platform for drug development. London-based venture capital firm Accel led the round, with participation from Air Street Capital and Elder Gull. The company, which currently has about 20 employees with most engineering in London, is already generating revenue from pharmaceutical clients including Australia's CSL, though it says multiple top-tier drug companies are using its software. Perceptic positions itself as the "connective tissue" that unifies disparate AI tools and data sources across the 15-year drug development process, targeting three key areas: scientific due diligence for biotech licensing assessments, clinical trial indication selection, and clinical trial data extraction. The platform is designed to be "infrastructure and model agnostic," allowing pharma companies to plug in their own data and AI systems while Perceptic harmonizes public, proprietary, and external datasets. The AI industry continues to generate extraordinary wealth, with 19 new AI billionaires emerging in the past year from specialized AI agent startups, according to a Bloomberg analysis. These founders have accumulated a combined fortune of approximately $59.3 billion, representing the so-called "second wave" of AI wealth following the initial rise of general-purpose AI model companies. Among the notable beneficiaries are Ioannis Antonoglou and Misha Laskin of Reflection AI, which creates AI agents capable of programming and debugging code, each amassing fortunes estimated at $4 billion. In healthcare, Daniel Nadler's OpenEvidence has grown to a $12 billion valuation with over 100 million AI consultations, making Nadler one of the wealthiest at approximately $7.2 billion. Winston Weinberg and Gabe Pereyra of Harvey, which provides AI agents for legal research and contract review, each hold roughly $1.6 billion. The Perceptic investment reflects a broader enterprise AI trend toward unified platforms that replace siloed workflows and traditional databases, according to Accel partner Sonali De Rycker. The venture firm began tracking Perceptic's founders while they were still at Palantir, where they were key engineers on the AIP platform, investing roughly a year after first meeting them once they had moved beyond pilot programs into paid production deployments. Nathan Benaich of Air Street Capital argued that pharmaceutical R&D breakthroughs will come not from incremental point solutions but from operating systems that connect data, decisions, and context across lengthy development timelines. Meanwhile, the surge of specialized AI agent billionaires includes diverse profiles such as Peter Thiel Fellowship dropouts from Mercor, an autodidact immigrant in Vercel's Guillermo Rauch, and former Google DeepMind researchers, underscoring how the AI transformation is creating wealth across varied backgrounds and use cases beyond the general AI models that dominated the first wave.